Pfizer partners with molecular glue startup Triana in $49M upfront deal

Ryan Cross

Senior Science Correspondent

Pfizer is deepening its investment in protein degraders through a new partnership with Triana Biomedicines, a startup working in the trendy field of molecular glues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer partners with molecular glue startup Triana in $49M upfront deal

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

J&J trims pipeline, including two mid-stage neuroscience studies

Forbion raises €2.1B for two new biotech funds after series of company exits

Maryland biotech gets green light for stem cell-derived therapy for diabetes, aiming to compete with Vertex

Exclusive: Biotech tools company raises $75M for protein manufacturing tech

Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Pfiz­er part­ners with mol­e­c­u­lar glue start­up Tri­ana in $49M up­front deal

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Pfizer partners with molecular glue startup Triana in $49M upfront deal